Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease.
Hoth Therapeutics (NASDAQ: HOTH) and Silo Pharma (NASDAQ: SILO) have formed a 50/50 joint venture to develop and commercialize a novel obesity treatment licensed from the U.S. Department of Veterans Affairs. The therapy is based on Glial Cell Line-Derived Neurotrophic Factor (GDNF), targeting obesity and non-alcoholic fatty liver disease (NAFLD).
The technology, protected under U.S. Patent No. 10,052,362, aims to address a $100B+ market with potential applications for type 2 diabetes and central obesity. The partnership combines the VA's clinical infrastructure, Hoth's regulatory expertise, and Silo's translational capabilities to develop this first-in-class treatment targeting the neuroinflammatory root of obesity.
Hoth Therapeutics (NASDAQ: HOTH) e Silo Pharma (NASDAQ: SILO) hanno costituito una joint venture al 50/50 per sviluppare e commercializzare un nuovo trattamento per l'obesità concesso in licenza dal Dipartimento per gli Affari dei Veterani degli Stati Uniti. La terapia si basa sul Fattore Neurotrofico Derivato dalle Cellule Gliali (GDNF), mirato all'obesità e alla steatosi epatica non alcolica (NAFLD).
La tecnologia, protetta dal Brevetto USA n. 10.052.362, punta a servire un mercato superiore ai 100 miliardi di dollari con potenziali applicazioni per il diabete di tipo 2 e l'obesità centrale. La partnership unisce l'infrastruttura clinica del VA, l'esperienza regolatoria di Hoth e le capacità traslazionali di Silo per sviluppare questo trattamento innovativo che agisce sulla radice neuroinfiammatoria dell'obesità.
Hoth Therapeutics (NASDAQ: HOTH) y Silo Pharma (NASDAQ: SILO) han formado una empresa conjunta al 50/50 para desarrollar y comercializar un nuevo tratamiento para la obesidad licenciado por el Departamento de Asuntos de Veteranos de EE.UU. La terapia se basa en el Factor Neurotrófico Derivado de Células Gliales (GDNF), dirigido a la obesidad y la enfermedad hepática grasa no alcohólica (NAFLD).
La tecnología, protegida bajo la Patente de EE.UU. No. 10,052,362, busca atender un mercado de más de 100 mil millones de dólares con posibles aplicaciones para la diabetes tipo 2 y la obesidad central. La asociación combina la infraestructura clínica del VA, la experiencia regulatoria de Hoth y las capacidades traslacionales de Silo para desarrollar este tratamiento innovador que aborda la raíz neuroinflamatoria de la obesidad.
Hoth Therapeutics (NASDAQ: HOTH)와 Silo Pharma (NASDAQ: SILO)는 미국 재향군인부로부터 라이선스를 받은 새로운 비만 치료제를 개발 및 상용화하기 위해 50대 50 합작 회사를 설립했습니다. 이 치료법은 글리알 세포 유래 신경영양 인자(GDNF)를 기반으로 하며, 비만과 비알코올성 지방간 질환(NAFLD)을 목표로 합니다.
미국 특허 번호 10,052,362로 보호되는 이 기술은 1000억 달러 이상의 시장을 겨냥하며 제2형 당뇨병과 중심성 비만에 대한 잠재적 적용 가능성을 가지고 있습니다. 이 파트너십은 VA의 임상 인프라, Hoth의 규제 전문성, Silo의 전임상 및 임상 개발 역량을 결합하여 비만의 신경염증 근본 원인을 겨냥한 이 혁신적인 치료법을 개발합니다.
Hoth Therapeutics (NASDAQ : HOTH) et Silo Pharma (NASDAQ : SILO) ont formé une coentreprise à parts égales pour développer et commercialiser un nouveau traitement contre l'obésité licencié par le Département des Anciens Combattants des États-Unis. La thérapie est basée sur le Facteur Neurotrophique Dérivé des Cellules Gliales (GDNF), ciblant l'obésité et la stéatose hépatique non alcoolique (NAFLD).
La technologie, protégée par le brevet américain n° 10 052 362, vise un marché de plus de 100 milliards de dollars avec des applications potentielles pour le diabète de type 2 et l'obésité centrale. Ce partenariat combine l'infrastructure clinique du VA, l'expertise réglementaire de Hoth et les capacités translationnelles de Silo pour développer ce traitement innovant de première classe ciblant la racine neuro-inflammatoire de l'obésité.
Hoth Therapeutics (NASDAQ: HOTH) und Silo Pharma (NASDAQ: SILO) haben ein 50/50 Joint Venture gegründet, um eine neuartige Behandlung gegen Fettleibigkeit zu entwickeln und zu vermarkten, die vom US Department of Veterans Affairs lizenziert wurde. Die Therapie basiert auf dem Glia-Zelllinien-abgeleiteten neurotrophen Faktor (GDNF) und richtet sich gegen Fettleibigkeit und nicht-alkoholische Fettlebererkrankung (NAFLD).
Die Technologie, geschützt durch das US-Patent Nr. 10.052.362, zielt auf einen Markt von über 100 Milliarden US-Dollar ab und bietet potenzielle Anwendungen bei Typ-2-Diabetes und zentraler Adipositas. Die Partnerschaft vereint die klinische Infrastruktur des VA, die regulatorische Expertise von Hoth und die translationalen Fähigkeiten von Silo, um diese bahnbrechende Behandlung zu entwickeln, die die neuroinflammatorische Ursache von Fettleibigkeit adressiert.
- Exclusive U.S. license from VA for a potentially disruptive obesity treatment
- Equal 50/50 partnership structure ensuring aligned interests
- Large addressable market of over $100B
- Protected intellectual property with U.S. Patent No. 10,052,362
- Multiple potential indications including obesity, NAFLD, and type 2 diabetes
- Technology still in preclinical stage with no human trial data
- Will require significant development time and resources to reach market
- Faces competition in crowded obesity treatment market
- No guarantee of clinical success or regulatory approval
Insights
Hoth-Silo joint venture targets massive obesity market with novel VA-licensed GDNF therapy; pre-clinical stage signals long development timeline ahead.
This 50/50 joint venture between Hoth Therapeutics and Silo Pharma represents a strategic entry into the rapidly expanding obesity treatment landscape. The exclusive license of GDNF-based technology from the VA gives them access to a potentially novel mechanism of action in a field currently dominated by GLP-1 agonists like Wegovy and Ozempic.
The
The dual targeting of obesity and non-alcoholic fatty liver disease (NAFLD) is scientifically logical as these conditions frequently co-occur. However, the mechanism - using Glial Cell Line-Derived Neurotrophic Factor to potentially address the "neuroinflammatory root of obesity" - represents a novel and unproven approach compared to established metabolic targets.
Patent protection through 2036+ (based on US Patent No. 10,052,362) provides reasonable runway if development proves successful. The equal partnership structure indicates shared risk and reward, with neither company assuming dominant control.
For context, both companies are small-cap biotechs with this joint venture potentially representing a significant portion of their development pipelines and future valuation potential.
*Hoth Therapeutics and Silo Pharma Launch Joint Venture to Commercialize VA-Invented Obesity Drug Targeting
Exclusive License from
The novel therapeutic platform centers on Glial Cell Line-Derived Neurotrophic Factor (GDNF), a VA-invented biologic with demonstrated anti-obesity effects and metabolic regulation in preclinical models. The platform is protected under
"This VA-originated obesity technology has the potential to disrupt a
"With obesity at epidemic levels and no curative therapies available, we believe GDNF is a game-changer," added Eric Weisblum, CEO of Silo Pharma. "This collaboration with Hoth and the VA aligns with our mission to accelerate groundbreaking science into human trials."
Deal Highlights:
- Exclusive
U.S. License from theU.S. Department of Veterans Affairs covering all fields of use - 50/50 Joint Venture structure with equal equity and governance participation
- Lead Indication: Obesity and NAFLD —
Unmet Need
**Obesity affects over
Strategic Alignment
This partnership leverages:
- The clinical infrastructure and public mission of the VA
- Hoth's regulatory and development expertise
- Silo's translational capabilities and capital efficiency
*https://www.pharmaceutical-technology.com/analyst-comment/obesity-market-173-5-billion-2031/#:~:text=Data%20Insights,of%20patients%20treated%20with%20pharmacotherapy.
**https://www.cbsnews.com/news/obesity-rate-us-adults-cdc-data-map/
About Hoth Therapeutics, Inc.
Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. To learn more, please visit https://ir.hoththerapeutics.com/ .
Forward-Looking Statement
This press release includes forward-looking statements based upon Hoth's current expectations, which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties, and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, and the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems, or the global economy as a whole; our intellectual property; our reliance on third-party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, and timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans, and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms, or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section titled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance, or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events, or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.
Investor Contact:
LR Advisors LLC
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791
View original content to download multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-hoth-and-silo-pharma-nasdaq-silo-today-announced-the-formation-of-a-5050-joint-venture-to-develop-a-first-in-class-gdnf-based-therapy-licensed-from-the-us-department-of-veterans-affairs-the-therapy-targe-302490308.html
SOURCE Hoth Therapeutics, Inc.
FAQ
What is the joint venture between Hoth Therapeutics (HOTH) and Silo Pharma about?
What is the market potential for HOTH's obesity treatment?
What makes HOTH's obesity treatment different from existing therapies?
What is the current development stage of HOTH's obesity treatment?
How will the partnership between HOTH and Silo Pharma work?
